The study aims to assess the fluence distribution and point dosage between two phantoms for patient-specific quality assurance on the Tomotherapy system. This was a retrospective study conducted on 15 patients who had radiation using the Helical Tomotherapy Machine (Radixact, Accuray Inc.). We used two phantoms to quantify the fluence produced by the treatment planning system (TPS) and recorded from the machine. The ArcCHECK (Sun-Nuclear) has 1386 diodes placed in a cylindrical configuration. The minimal resolution for this was 7 mm. The second was Delta 4 , supplied by ScandiDos. It has 1069 diode detectors arrayed in a crossed orthogonal configuration with a minimum resolution of 5 mm. All patient plans were transferred to these phantoms to validate the accuracy of treatment plan delivery. We used SunCHECK and ScandiDos Delta 4 software to compare the fluence produced by the TPS with the fluence measured by the equipment. In ArcCHECK, we used an external ionization chamber, cc13 (IBA dosimetry), whereas in Delta 4 ,we employed a central diode detector to quantify point dosage. The mean and standard deviation of the gamma pass percentage with ArcCHECK were 98.3 ± 0.8%, with an average point dose deviation of ± 0.94%. The mean and standard deviation of the gamma pass percentage using Delta 4 was 99.1 ± 1.6%, while the average point dose deviation was ± 0.60%, both of which were well within the 3% tolerance employing the two phantoms.
Aim: This study aimed to evaluate the multifaceted clinical utility of the RUBY phantom as a comprehensive quality assurance (QA) platform in high-precision radiotherapy, particularly for stereotactic radiosurgery (SRS) and stereotactic radiotherapy (SRT). The objective was to validate its performance in patient positioning, imaging system accuracy, isocenter congruency, and treatment plan verification across various complex clinical scenarios. Materials and methods: A series of QA workflows were conducted using the RUBY phantom and its dedicated modular inserts. These included CBCT and MV/kV planar imaging for patient alignment, the Winston-Lutz insert for isocenter verification, end-to-end testing for full-chain validation, and multi-metastasis and patient-specific inserts for point dose verification. Plans were created in Eclipse TPS (v15.6) and delivered using a Varian TrueBeam STx linear accelerator with high-definition MLC. PTW Semiflex 3D and PinPoint 3D ionization chambers were used for all dosimetric verifications. Results: CBCT- and planar image-guided alignments showed sub-millimetric deviations, with post-correction alignment verified through coincident laser and surface markers. Winston-Lutz testing across various angles demonstrated maximal deviations of ≤ 0.4 mm, which was within TG-142 recommendations. Point dose measurements for 61 SRS plans showed agreement within ± 3% of TPS calculations. End-to-end testing revealed dose discrepancies of < 1% in both coplanar and non-coplanar beam arrangements. Multi-target plans using single- and multi-isocenter approaches showed deviations of − 0.23% to − 0.50%, confirming excellent dosimetric and geometric accuracy. Conclusion: The RUBY phantom demonstrated exceptional precision, reproducibility, and clinical adaptability across a spectrum of advanced radiotherapy QA tasks. Its integration enables the end-to-end validation of modern treatment protocols, ensuring alignment, imaging, and accuracy of dose delivery. These findings establish the RUBY phantom as a cornerstone QA solution for enhancing safety, efficacy, and reliability in high-precision radiotherapy.